Literature DB >> 12180896

The management of rosacea.

Alfredo Rebora1.   

Abstract

Rosacea is a multiphasic disease which is associated with flushing, erythrosis, papulopustular rosacea and phymas; each phase is likely to have its own treatment. Flushing is better prevented rather than treated, and its etiology investigated. Beta-blockers, atenolol in particular, are worthy of prophylactic trials examining their efficacy in treating the flushing associated with rosacea. Currently, clonidine is the only drug available for the treatment of flushing. Treatment for erythrosis includes topical and systemic therapies. Metronidazole 1% cream and azelaic acid 20% cream have been reported to reduce the severity score of erythema. The systemic treatment of erythrosis is based on the association of Helicobacter pylori with rosacea. However, this role is still being debated. Eradication of H. pylori can be achieved using a triple therapy regimen lasting 1 to 2 weeks [omeprazole and a combination of two antibacterials (a choice from clarithromycin, metronidazole or amoxicillin)]. Both the flashlamp-pumped long-pulse dye laser and the potassium-titanyl-phosphate laser may be used in the treatment of facial telangiectases. Both systemic and topical remedies may be used to treat the papulopustules of rosacea. Systemic treatment includes metronidazole, doxycycline, minocycline, clarithromycin and isotretinoin, while topical treatment is based on metronidazole cream and gel. The presence of Demodex folliculorum is important in the inflammatory reaction, whether it is pathogenetic or not. Crotamiton 10% cream or permethrin 5% cream may be useful medications for papulopustular rosacea, although they are rarely successful in eradicating D. folliculorum. Oral or topical ivermectin may also be useful in such cases. Ocular involvement is common in patients with cutaneous rosacea and can be treated with orally administered or topical antibacterials. Once rhinophyma starts to be evident, the only way to correct it is by aggressive dermatosurgical procedures. Decortication and various types of lasers can also be used. Associated conditions, such as seborrheic dermatitis and possible contact sensitizations, deserve attention.

Entities:  

Mesh:

Year:  2002        PMID: 12180896     DOI: 10.2165/00128071-200203070-00005

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  10 in total

1.  Use of oral isotretinoin in the management of rosacea.

Authors:  Hyunhee Park; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

2.  Rosacea: a review.

Authors:  Brittney Culp; Noah Scheinfeld
Journal:  P T       Date:  2009-01

Review 3.  [Rosacea. Clinical features, pathogenesis and therapy].

Authors:  P Lehmann
Journal:  Hautarzt       Date:  2005-09       Impact factor: 0.751

Review 4.  Rosacea Management.

Authors:  Manal Abokwidir; Steven R Feldman
Journal:  Skin Appendage Disord       Date:  2016-05-18

5.  Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

6.  Staining of palatal torus secondary to long term minocycline therapy.

Authors:  Aravind Buddula
Journal:  J Indian Soc Periodontol       Date:  2009-01

Review 7.  Cutaneous lesions of the nose.

Authors:  Michael Sand; Daniel Sand; Christina Thrandorf; Volker Paech; Peter Altmeyer; Falk G Bechara
Journal:  Head Face Med       Date:  2010-06-04       Impact factor: 2.151

Review 8.  Helicobacter pylori infection and eye diseases: a systematic review.

Authors:  Sergio Claudio Saccà; Aldo Vagge; Alessandra Pulliero; Alberto Izzotti
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 9.  Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments.

Authors:  Martin Steinhoff; Marc Vocanson; Johannes J Voegel; Feriel Hacini-Rachinel; Gregor Schäfer
Journal:  Adv Ther       Date:  2016-07-18       Impact factor: 3.845

10.  The effect of systemic Isotretinoin on salivary tissue inhibitors of metalloproteinases 1 and 2 and salivary flow rate in periodontal disease.

Authors:  Reham AlJasser; Razan AlAqeely; Manal AlKenani; Sadeem AlQahtani; Afnan AlZahrani; Rhodanne Lambarte
Journal:  Saudi J Biol Sci       Date:  2021-08-28       Impact factor: 4.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.